Inavolisib Patent Expiration
Inavolisib was first introduced by Genentech Inc
Inavolisib Patents
Given below is the list of patents protecting Inavolisib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Itovebi | US12410189 | Polymorphs And Solid Forms Of (S)-2-2((2-((S)-4-(Difluoromethyl)-2-Oxooxazolidin-3-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4]Oxazepin-9- Yl)Amino)Propanamide, And Methods Of Production | Jun 14, 2038 | Genentech Inc |
| Itovebi | US11028100 | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | Apr 26, 2038 | Genentech Inc |
| Itovebi | US10851091 | Benzoxazepin oxazolidinone compounds and methods of use | Jul 01, 2036 | Genentech Inc |
| Itovebi | US11760753 | Benzoxazepin oxazolidinone compounds and methods of use | Jul 01, 2036 | Genentech Inc |
| Itovebi | US9650393 | Benzoxazepin oxazolidinone compounds and methods of use | Jul 01, 2036 | Genentech Inc |
| Itovebi | US8242104 | Benzoxazepin P13K inhibitor compounds and methods of use | Sep 27, 2030 | Genentech Inc |
| Itovebi | US8343955 | Benzoxazepin PI3K inhibitor compounds and methods of use | Sep 27, 2030 | Genentech Inc |
Inavolisib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Inavolisib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
